Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

09-Nov-2011 - United Kingdom

Horizon Discovery Ltd.  announced a strategic partnership agreement with Promega Corporation. The partnership centers on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag® reporter technologies, using Horizon’s proprietary homologous recombination-based precision genome editing technology (rAAV GENESIS™).

The scientific objective of the partnership is to develop next-generation predictive human disease models, recapitulating genetic mutations exactly as they occur in patient tumors, thereby enabling the elucidation of protein expression and protein-protein interactions encoded by those mutations. To date, Horizon has applied its rAAV gene-editing platform to reconstitute over 370 cancer mutations and variations in human cell lines that serve as patient-relevant, predictive in vitro models of genetic disease.

Additional objective(s) will be to enable the study of tumor response to anti-cancer treatments in real-time, by offering in vivo xenografts of Horizon’s tumorigenic engineered isogenic cell lines with incorporated Promega reporter tags. Preliminary studies have revealed exceptionally clear images of tumor graft response to targeted molecular therapies. This capability adds to drug discovery scientists’ existing toolbox of patient relevant models to support the development of a greater number of more efficacious anti-cancer drugs.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances